<SEC-DOCUMENT>0001140361-17-015454.txt : 20170410
<SEC-HEADER>0001140361-17-015454.hdr.sgml : 20170410
<ACCEPTANCE-DATETIME>20170410170403
ACCESSION NUMBER:		0001140361-17-015454
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20170407
FILED AS OF DATE:		20170410
DATE AS OF CHANGE:		20170410

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bioptix, Inc.
		CENTRAL INDEX KEY:			0001167419
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				841553387
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		834-F SOUTH PERRY STREET, SUITE 443
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104
		BUSINESS PHONE:		303-794-2000

	MAIL ADDRESS:	
		STREET 1:		834-F SOUTH PERRY STREET, SUITE 443
		CITY:			CASTLE ROCK
		STATE:			CO
		ZIP:			80104

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Venaxis, Inc.
		DATE OF NAME CHANGE:	20121218

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AspenBio Pharma, Inc.
		DATE OF NAME CHANGE:	20051110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ASPENBIO INC
		DATE OF NAME CHANGE:	20020213

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Beeghley Michael Martin
		CENTRAL INDEX KEY:			0001662216

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33675
		FILM NUMBER:		17754171

	MAIL ADDRESS:	
		STREET 1:		1170 PEACHTREE ST.
		STREET 2:		SUITE 525
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30309
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc1.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2017-04-07</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001167419</issuerCik>
        <issuerName>Bioptix, Inc.</issuerName>
        <issuerTradingSymbol>BIOP</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001662216</rptOwnerCik>
            <rptOwnerName>Beeghley Michael Martin</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BIOPTIX, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>834-F SOUTH PERRY STREET, SUITE 443</rptOwnerStreet2>
            <rptOwnerCity>CASTLE ROCK</rptOwnerCity>
            <rptOwnerState>CO</rptOwnerState>
            <rptOwnerZipCode>80104</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Executive Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>4.02</value>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2017-04-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>20000</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0.00</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2027-04-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>20000</value>
                    <footnoteId id="F1"/>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>20000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">(1)	Represents a grant of an option to purchase the Company's common stock (the &quot;Options Award&quot;) at an exercise price equal to the fair market value on the date of issuance, as determined in accordance with NASDAQ rules, pursuant to the Company's 2016 Equity Incentive Plan (the &quot;2016 Plan&quot;). The Options Award shall vest in 24 equal monthly installments over a two year period, beginning on the one month anniversary of the date of issuance. The vesting of the Options Award is subject to acceleration upon the occurrence of a &quot;Qualifying Transaction&quot;, as such term is defined in the 2016 Plan.</footnote>
        <footnote id="F2">The Options Award was granted in connection with the Reporting Person's appointment as Chief Executive Officer of the Company.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Michael Beeghley</signatureName>
        <signatureDate>2017-04-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
